AbbVie sees negative Q2, full-year impact from IPR&D and milestones expense AbbVie sees negative Q2, full-year impact from IPR&D and milestones expense Post ContentabbvRead More You might also be interested in reading Meta in charts: ARPP and DAP rise from last year. July 3, 2025 In Mainstream ← Previous post Next post →